MPOX TRACKER

Tonix Pharmaceuticals has received a grant from the Medical CBRN Defense Consortium (MCDC) to further develop TNX-801, an innovative recombinant horsepox virus vaccine aimed at preventing mpox and smallpox. This funding supports market analysis, target identification, and commercialization planning for both private and government sectors. TNX-801 offers a single-dose solution with long-term immunity, potentially addressing the global need for improved mpox prevention strategies.

With the World Health Organization (WHO) reaffirming clade I mpox as a Public Health Emergency of International Concern (PHEIC) in February 2025, the urgency for an effective vaccine has intensified. The outbreak, originating in the Democratic Republic of the Congo, has now spread to 16 Central African nations and beyond, reaching China, Thailand, Singapore, India, Europe, Canada, and the United States. Traditional vaccinia-based vaccines, while effective, have raised concerns regarding tolerability, making TNX-801’s enhanced safety profile particularly significant.

TNX-801 has already demonstrated protective efficacy in preclinical models, offering immune defense against lethal intratracheal clade I mpox virus challenges. Its development aligns with ongoing global efforts to strengthen pandemic preparedness and control emerging infectious diseases. Given the increasing risk of mpox outbreaks worldwide, securing a more accessible, well-tolerated vaccine is paramount.

Tonix’s collaboration with MCDC highlights the critical intersection of public health security and biopharmaceutical innovation. As governments and health agencies seek scalable solutions for outbreak containment, TNX-801 represents a significant advancement in vaccine technology, with the potential to fortify both civilian and military defenses against future mpox threats.